15 April 2021
Visiongain has published a new report on Antibiotics Market Report 2021-2031: Forecasts by Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, Sulfonamide, 7-AC, Others), by Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, Others), by Gender (Male, Female), by Age (0-14 Years, 15-54 Years, 55 Years and Above), by Route of Administration (Oral, Intravenous, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Antibiotics Companies AND COVID-19 Recovery Scenarios.
Global antibiotics market size is projected to be valued at US$ xx million in 2020 and is further expected to reach US$ xx million in 2026 while growing at a CAGR of xx% during the first half of the forecast period i.e., 2021 to 2026. The global market size is further projected to reach US$ xx million by 2031 at a CAGR of xx% from 2026 to 2031. The overall CAGR for the global antibiotics market is expected to be xx% from 2021 to 2031.
Lack of Financial Incentives to Jeopardize Antibiotics Market Growth Through 2031
Visiongain concludes that the companies operating across the antibiotics market continue to leave the market due to a lack of profitability, thus anticipated to jeopardize research and development in the antibiotics industry. To avoid the spread of resistance, new antibiotics must be used sparingly, but small businesses cannot thrive on sales that do not cover operating costs. Antibiotics can become unavailable to patients if these companies go bankrupt or shift their focus to other therapeutic areas. While extensive research has been done on incentives to encourage antibiotic innovation, little attention has been paid to how these incentives are funded. Companies are not leaving because of a lack of push support, or funding that makes R&D simpler. Indeed, with actions at international levels, public and philanthropic support for AMR-related R&D has increased dramatically in the last 5 years. Companies are leaving as the antibiotics market becomes futile once a product is commercialized. In the United States, the total sales of five of the recent antibiotics are estimated to be below US$ 1 million monthly, which is unlikely to cover operating costs. For antibiotic stewardship, it is probably better to keep these new antibiotics on the shelf while older antibiotics are still successful. However, businesses, especially small businesses, cannot survive on such low revenues. Antibiotics can become unavailable to patients if these companies go bankrupt or shift their focus to other therapeutic areas.
Capability Expansion by Major Players to Offer Competitive Edge in Antibiotics Market
An important strategy that is being applied by companies operating in the antibiotics industry is to use acquisitions to expand their capabilities. This enables the continuous acquisition of resources required to maintain a competitive edge. Continuous development of existing resources and skills, as well as the acquisition of new ones, is required for businesses to retain or renew competitive advantage. New capabilities may be acquired by mergers, acquisitions, partnerships, or simply internal growth. Visiongain has analyzed in this report, that majority of the players are using acquisition as a standard method to build or acquire capabilities. Some companies acquire new companies to expand their operations in new geographical markets, while others acquire new companies to expand their product range. Acquisition can also occur as companies seek lower-cost manufacturing locations. Acquisition may also occur as governments mandate international firms to have a local presence, requiring them to either establish a new local business or purchase one. The latter is the first choice taken by the majority of antibiotics firms. Finally, acquisitions allow businesses to move rapidly and thus reach new markets with existing customers, minimise bureaucratic burdens associated with starting a company, and acquire technology that would otherwise take a long time and effort to create. These are some of the main reasons why companies in the antibiotics industry choose to improve their capabilities this way.
Antibiotic-resistant bacteria will inevitably emerge, resulting in reduced efficacy of conventional antibiotics as a result of widespread use. The traditional solution to this problem is to introduce new antibiotics that destroy resistant strains. Despite the conventional success of antibiotics, the pharmaceutical industry only develops a small number of antibiotics, particularly for Gram-negative bacteria. Furthermore, the government's increased efforts to prevent hospital-acquired infections (HAI), catheter-associated infections, and ventilator-associated infections will create lucrative opportunities for the market in the coming years.
The field of genomics has proven to be a fertile breeding ground for new antibiotics. In addition, non-culturable bacteria are a promising potential source. Bacteriophages have antibacterial properties in organisms and thus have the potential to be effective in specific infections. The introduction of new antibiotics targeting non-multiplying bacteria is another strategy that can lead to the development of new antibiotics for resistant strains while also improving patient compliance by reducing treatment length. These novel pathways have aided in the development of compounds in the preclinical stage, but they have yet to be tested in clinical trials. The majority of new antibiotics on the market are structural analogues of existing antibiotic families or novel natural or non-natural compounds that have been tested using traditional methods.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global antibiotics market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the antibiotics market. Some of the major companies operating in the global antibiotics market are Abbott Laboratories, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Viatris (Mylan), Novartis International AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Cipla Ltd., Allergan (AbbVie Inc.), Cumberland Pharmaceuticals, Inc., LUPIN, Melinta Therapeutics LLC, Amneal Pharmaceuticals LLC, and WOCKHARDT.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market